FDA Approves Anti-Epileptic Drug XCOPRI

FDA Approves Anti-Epileptic Drug XCOPRI

The FDA granted approval to SK Biopharmaceuticals, Co., Ltd. and its U.S. subsidiary SK Life Science, Inc. for XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adult patients.This approval is the first time that a Korean pharmaceutical company has independently brought a compound from discovery to U.S. FDA approval. WIth our global footprint, Yourway is well positioned to support international clinical trials.

Back to Index

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54



Agility and Flexibility in a Company That Provides Both Courier and Clinical Packaging Services